Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987909 | 0.92 | ADORA3 (0.33) | KMT2AMAPT | |
| SCHEMBL3985868 | 0.91 | KMT2A (0.31) | KMT2A | |
| SCHEMBL3985932 | 0.91 | P2RX7 (0.31) | KMT2AP2RX7AVPR1BPTGER4FSCN1 | |
| SCHEMBL3982499 | 0.90 | ALDH1A1 (0.43) | KMT2AMAPTALDH1A1AVPR1BPTGER4 | |
| SCHEMBL3983880 | 0.86 | PTGER4 (0.33) | P2RX7AVPR1BPTGER4FSCN1 | |
| SCHEMBL3990945 | 0.86 | P2RX7 (0.36) | P2RX7PTGER4FSCN1 | |
| SCHEMBL3985844 | 0.85 | AVPR1B (0.33) | P2RX7AVPR1BPTGER4 | |
| SCHEMBL3985457 | 0.85 | PTGER4 (0.32) | P2RX7AVPR1BPTGER4FSCN1 | |
| SCHEMBL3987901 | 0.85 | AVPR1B (0.31) | AVPR1B | |
| SCHEMBL3984334 | 0.85 | AVPR1B (0.34) | P2RX7AVPR1BPTGER4FSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | claimed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | KMT2A 1226/4885MAPT 3743/4885ALDH1A1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.